美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Dolasetron Mesylate	Tablet			Develop a dissolution method			2024/01/03
Dolutegravir Na/Rilpivirine HCl	Tablet	II (Paddle)	75	1.0 % Tween 20 in 0.01 M HCl, pH 2.0	900	10, 15, 20, 30, 45 and 60	2018/02/08
Dolutegravir Sodium (10 mg)	Tablet	II (Paddle)	50	0.01M pH 6.8 phosphate buffer	900	5, 10, 15, 20, 30 and 45	2018/10/18
Dolutegravir Sodium (25 mg)	Tablet	II (Paddle)	50	0.01M pH 6.8 phosphate buffer containing 0.15% w/v sodium dodecyl sulfate (SDS)	900	5, 10, 15, 20, 30 and 45	2018/10/18
Dolutegravir Sodium (50 mg)	Tablet	II (Paddle)	50	0.01M pH 6.8 phosphate buffer containing 0.25% w/v sodium dodecyl sulfate (SDS)	900	5, 10, 15, 20, 30 and 45	2018/10/18
Donepezil HCl/Memantine HCl	Capsule (Extended Release)	I (Basket)	100	pH 1.2 NaCl/HCl buffer	900	Donepezil: 5, 10, 15, 20 and 30 minutes; Memantine: 1, 2, 3, 4, 6, 8, 10 and 12 hours	2015/05/28
Donepezil HCl	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Donepezil HCl	Tablet (Orally Disintegrating (ODT))	II (Paddle)	50	0.1 N HCl	900	10, 20, 30 and 45	2006/03/04
Donepezil HCl	Transdermal	V (Paddle over disk) with Transdermal System Holding Wire Screen (TSHWR)	100	0.02 M sodium acetate buffer, pH 4.5 at 32°C	900	1,8,24,48 and 168 hours	2023/05/18
Donepezil HCl (23 mg)	Tablet	II (Paddle	50	0.05 M Phosphate Buffer, pH 6.8	900	1, 2, 3, 4, 6, 8 and 10 hours	2010/12/23
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate	Tablets	II (Paddle)	75	25 mM Phosphate Buffer, pH 6.8 with 3% Polysorbate 80	900	5, 10, 15, 20, 30, 45, 60 and 90	2023/10/06
Dordaviprone Hydrochloride	Capsule	I (Basket)	100	0.1 N HCl	500	5, 10, 15, 20, 30, 45 and 60	2026/03/25
Doxazosin Mesylate	Tablet	II (Paddle)	50	0.01 N HCl	900	10, 20, 30, 45 and 60	2004/01/27
Doxazosin Mesylate	Tablet (Extended Release)	II (Paddle)	75	SGF without enzyme	900	1, 2, 4, 6, 8, 12 and 16 hours	2007/01/03
Doxepin HCl	Tablet	II (Paddle)	50	Simulated Gastric Fluid w/o enzyme (pH 1.1-1.3)	900	5, 10, 15, 20, 30 and 45	2010/09/02
Doxepin HCl	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Doxepin HCl	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Doxercalciferol	Capsule			Develop a quantitative rupture test			2008/06/03
Doxorubicin HCl	Injectable (Liposomal)			Develop a method to characterize in vitro release, starting at pH 6.00 ± 0.05 and at 47ºC ± 0.5ºC. Replicate for 12 dosage vials.			2012/10/04
Doxycycline	Capsule (Delayed Release)	II (Paddle)	75	Dilute HCl, pH 1.1 for 2 hours and then add 200 mL of 0.1 N NaOH in 200 mM Phosphate Buffer. Adjust pH to 6.0 using 2 N HCl and/or 2N NaOH	Acid stage: 750; Buffer stage: 950	1, 2, 2.5 , 3 and 4 hours	2008/10/06